Salarius Pharmaceuticals, Inc. (SLRX)
NASDAQ: SLRX · Real-Time Price · USD
0.825
-0.046 (-5.23%)
At close: Dec 5, 2025, 4:00 PM EST
0.880
+0.055 (6.67%)
After-hours: Dec 5, 2025, 7:59 PM EST
Company Description
Salarius Pharmaceuticals, Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing.
Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture peptide conjugates targeting various unmet medical needs.
The company focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology.
Salarius Pharmaceuticals, Inc. is based in Houston, Texas.
Salarius Pharmaceuticals, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Frederick Pierce |
Contact Details
Address: 2450 Holcombe Blvd., Suite X Houston, Texas 77021 United States | |
| Phone | 713 913 5608 |
| Website | salariuspharma.com |
Stock Details
| Ticker Symbol | SLRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001615219 |
| CUSIP Number | 79400X503 |
| ISIN Number | US79400X5032 |
| Employer ID | 46-5087339 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Frederick E. Pierce II | Chief Executive Officer |
| Jodi Cooper M.S. | Director of Operations |
| Dr. Michael M. Lipp Ph.D. | Chief Technology Officer |
| Barb Hibner Ph.D. | Chief Scientific Officer |
| Dr. Shahin Gharakhanian DPH, M.D. | Chairman of the Scientific Advisory Board and Acting Chief Medical Officer |
| Peter K. Marschel M.B.A., M.S. | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 19, 2025 | 8-K | Current Report |
| Nov 18, 2025 | SCHEDULE 13G | Filing |
| Nov 17, 2025 | 8-K | Current Report |
| Nov 14, 2025 | 10-Q | Quarterly Report |
| Nov 14, 2025 | SCHEDULE 13G | Filing |
| Nov 13, 2025 | 8-K | Current Report |
| Nov 12, 2025 | 424B4 | Prospectus |
| Nov 10, 2025 | FWP | Free Writing Prospectus |
| Nov 7, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 7, 2025 | DEF 14A | Other definitive proxy statements |